The effect of L-Carnitine on plasma Albomin level in peritoneal dialysis patients
Phase 2
- Conditions
- peritoneal dialysis patients.End-stage renal disease
- Registration Number
- IRCT138806022370N1
- Lead Sponsor
- Isfahan University of medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
age upper than 21, have history of peritoneal dialysis
at least for one month before, having informed consent, no history of carnitine use in previous 8 weeks, no history of infectious disease or fever in previous month. Exclusion criteria: having side effects after taking tablets (like hypertension, dizziness, blurred vision, minimental status, vomiting and diarrhea), person who want to exit from the study,having an infectious problem or antibiotic usage or if a patient change the dialysis method, migrate from the center, having renal transplantation .
If a patients need iron complements or Erythropoetin or blood infusion or have gastrointestinal bleeding, exclude from Hemoglobin study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Albomin. Timepoint: every 3 months. Method of measurement: Bromocresol Green Method.
- Secondary Outcome Measures
Name Time Method CRP. Timepoint: first month and 9th month. Method of measurement: torbidometry.;Lipid profile ( HDL, LDL, Chol, Triglyceride). Timepoint: first month and 9th month. Method of measurement: Enzymatic and percipitant method.;Homocystein. Timepoint: first month and 9th month. Method of measurement: Elisa.;Hemoglobin. Timepoint: first month and 9th month. Method of measurement: H3.